Cartalax

Cartalax works through systemic effects on fibroblasts and gene expression. Once in circulation, it reaches fibroblasts throughout connective tissue, stimulating collagen production and suppressing matrix-degrading enzymes like MMP-9. This systemic fibroblast activation supports cartilage maintenance and collagen preservation even in avascular cartilage.

Russian clinical studies show efficacy in established osteoarthritis, osteochondrosis, and osteoporosis treatment. However, 'reverse' is overstated—Cartalax supports tissue repair and slows degeneration better than it rebuilds severely damaged cartilage. Results are best when cartilage damage is moderate, not advanced.

Week 1-2 establishes baseline; minimal noticeable changes. Week 3-4 brings gradual improvement in joint comfort. Month 2 shows noticeable mobility improvements. Month 3 achieves maximum therapeutic effect. Results are cumulative with repeat cycles; 1-3 month cycles repeated annually produce best long-term joint health.

Cartalax increases fibroblast proliferation while suppressing apoptosis. Theoretical concern exists regarding uncontrolled cell growth, but Russian clinical practice spanning decades shows no documented malignancy risk. Avoid use in active cancer; for healthy individuals, cyclic use (1-3 months on, breaks between) minimizes theoretical proliferation risk.